AI Article Synopsis
- Amitriptyline, marketed as Elavil since 1961, is the second tricyclic antidepressant and has proven effective for major depressive disorder while raising concerns about cardiotoxicity.
- It works by inhibiting the reuptake of serotonin and norepinephrine, impacting various receptors and contributing to the understanding of mood disorders through the monoamine theory.
- The review covers amitriptyline's synthesis, manufacturing, metabolism, pharmacology, adverse effects, and its significance in therapy, highlighting its status in chemical neuroscience.
Article Abstract
Amitriptyline was the second tricyclic antidepressant to appear on the market for major depressive disorder under the brand name Elavil in 1961. Since its emergence, amitriptyline has been an effective therapeutic in various disease states and disorders but has also been a concerning source of cardiotoxicity. Amitriptyline inhibits serotonin and norepinephrine reuptake as well as produces off-target activity at histaminergic, muscarinic, and various other receptors. Its role as a modulator of monoamines helped further establish the monoamine theory to understand various mood disorders, paving the way for the now more common selective serotonin/norepinephrine reuptake inhibitors. In this review, we will discuss amitriptyline's synthesis, manufacturing information, drug metabolism, pharmacology, adverse effects, and its history and importance in therapy to present amitriptyline as a true classic in chemical neuroscience.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acschemneuro.0c00467 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!